BI Asset Management Fondsmaeglerselskab A S Invests $5.10 Million in Celcuity, Inc. $CELC

BI Asset Management Fondsmaeglerselskab A S purchased a new position in Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 51,155 shares of the company’s stock, valued at approximately $5,102,000.

Other hedge funds have also recently bought and sold shares of the company. WINTON GROUP Ltd acquired a new position in Celcuity during the fourth quarter worth $763,000. TD Asset Management Inc increased its position in shares of Celcuity by 34.0% in the fourth quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock valued at $9,727,000 after buying an additional 24,730 shares in the last quarter. COFG Advisors LLC purchased a new stake in shares of Celcuity in the 4th quarter worth about $1,226,000. Norges Bank acquired a new stake in Celcuity in the 4th quarter valued at about $1,317,000. Finally, SBI Okasan Asset Management Co.Ltd. acquired a new stake in Celcuity in the 4th quarter valued at about $660,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CELC has been the subject of a number of research reports. Wolfe Research restated an “outperform” rating and set a $110.00 target price on shares of Celcuity in a research report on Thursday, March 12th. Wells Fargo & Company lowered their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday. Macquarie Infrastructure set a $160.00 target price on Celcuity in a research note on Thursday, May 28th. Citizens Jmp increased their target price on Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a report on Monday, May 4th. Finally, Needham & Company LLC reissued a “buy” rating and set a $157.00 price target on shares of Celcuity in a research report on Friday, May 15th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $152.09.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,000 shares of company stock worth $5,111,950 over the last three months. Corporate insiders own 13.33% of the company’s stock.

Celcuity Stock Performance

Shares of CELC opened at $88.28 on Monday. The stock has a fifty day moving average of $122.01 and a two-hundred day moving average of $111.52. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The company has a market capitalization of $4.31 billion, a PE ratio of -22.64 and a beta of 0.10. Celcuity, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $151.02.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, analysts forecast that Celcuity, Inc. will post -3.69 EPS for the current year.

Key Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $145 price target on Celcuity, and its longer-term forecasts still imply meaningful profitability potential by 2028-2030.
• Neutral Sentiment: The company also announced an upsized $500 million convertible senior notes offering due 2032, which improves funding for development but also raises dilution concerns for shareholders. Celcuity Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
• Neutral Sentiment: Celcuity expanded its Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients, a development that could broaden the market opportunity if the study continues to progress well. Celcuity Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates for Celcuity, including lower projections for FY2026, FY2027, FY2028, FY2029, and Q4 2026, signaling expectations for continued losses before eventual profitability.
• Negative Sentiment: Investor sentiment also appears to have been hurt by reports that Celcuity shares fell after trial results disappointed some investors, even though other coverage described the late-stage breast cancer data as potentially strong or “practice-changing.” ASCO26: Celcuity punished as trial disappoints investors

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.